ACROSS ONCOLOGY. WORLDWIDE

Josep Tabernero

ESMO President

Wednesday, 14th February 2018

ESMO

ESMO IN A NUTSHELL

Europe’s leading Medical Oncology Society

ESMO is the leading European professional organisation for

medical oncology, working across Europe and around the world

to erase boundaries in cancer care and to provide medical

oncology education within an integrated approach to cancer

care

ESMO MISSION

Improve the quality of prevention, diagnosis, treatment, supportive

and palliative care

Disseminate knowledge in oncology to cancer patients and

the public

Facilitate equal access to optimal cancer care for all

cancer patients

Maintain liaisons with other oncology

specialties, cancer leagues, universities,

patient groups & where appropriate, the pharmaceutical

industry

Advance the art, science, recognition,

and practice of oncology

Promote education in oncology to ensure a

high standard of qualification for

medical oncologists within the

multidisciplinary team

Educate and train persons involved in

clinical cancer care and research

ESMO 2020 VISIONSecuring the best possible outcomes for people with cancer

Membership

ConferencesPublic Policy

Career Development

OncologyProClinical Practice

ESMO MEMBERSHIP AND GLOBAL NETWORK

Membership Distribution

North America 9%

South America 6%

Europe 55%

Africa 5%

Asia-Pacific 25%

As of 31 December 2017

> 18,000 members

Over 150 countries

Reciprocal membership

with 50 national oncology societies

5,661 6,306 6,7867,371 7,356

11,49613,221

15,295

18,213

0

5000

10000

15000

20000

2009 2010 2011 2012 2013 2014 2015 2016 2017

ESMO MEMBERSHIP GROWTH 2009-2017

222% increase over last 9 years

AFRICA: 875 MEMBERS

Algeria 108

Angola 2

Botswana 1

Cameroon 2Congo, Democratic Republic of 2Congo, Republic of 1

Côte d'Ivoire 1

Egypt 402

Eritrea 1

Ethiopia 2

Guinea-Bissau 1

Kenya 11

Libya 11

Malawi 1

Mali 1

Mauritania 2

Mauritius 4

Morocco 77

Namibia 6

Nigeria 13

Senegal 2

South Africa 124

Sudan 20

Tanzania 2

Tunisia 52

Uganda 8

Zambia 1

Zimbabwe 8

Membership figures at 31.12.2017

SOUTH AFRICA: 124 MEMBERS

DEVELOPING COUNTRIES DISCOUNTED FEES

ESMO offers a reduced membership fee of € 25 or € 50 to oncology professionals from developing countries.

This 'two tier' structure uses the World Bank classification of low, lower-middle and upper-middle countries based on the Gross National Income (GNI) per capita and calculated using the World Bank Atlas method.

ESMO SUMMIT AFRICA SPECIAL ONSITE MEMBERSHIP OFFER

One free year of membership offered to all registered delegates

More information at the ESMO booth in the Exhibition

Jill MaddenHead of Membership

TOOLS AND RESOURCESOncologyPRO – ESMO’s online education portal

Scientific and educational online portal

Direct access 24/7 to

oncology news, scientific

and educational resources

Information by disease-type

Continuously updated

DISSEMINATING CANCER INFORMATION WORLDWIDE

The official journal of ESMO, providing rapid and efficient peer-review publications on innovative

cancer treatments, or translational work related to oncology and

precision medicine.

Ranked #10 in Oncology; IF 11.855

•Over 4.3x10 million downloads in 2016

•Accessed by 3,569 institutions worldwide

•Over 2 million unique readers in 188 countries

•Over 15,000 followers on Twitter

•Official journal of JSMO

ESMO’s online-only, peer-reviewed open access journal, dedicated to

publishing high-quality medical research and educational content from all disciplines of oncology.

Indexing: Google Scholar, PubMed Central, Emerging Sources Citation Index (Web of Science)

•Global reach: 241 submissions from 34 countries

•Broad coverage: 157 papers published

•Affiliations with AIOM, CSCO, KACO, JSMO

SETTING THE STANDARDS OF CARE FOR CLINICAL CANCER PRACTICE

ESMO Clinical Practice Guidelines

Evidence-based

guidelines to support

clinicians in delivering

patients the best cancer treatment

options

Latest information

on diagnostic criteria, disease

staging, risk assessment, treatment plan and follow-up

Regularly updated and reviewed by

leading oncology experts

More than 70 available from the

ESMO website or the ESMO

mobile app

Approximately 20 patient

friendly versions available

ESMO MEETINGS

Exchange expertise and knowledge at our first class events

Congresses Symposia Educational Courses

PROMOTING SUSTAINABLE CANCER CAREESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS)

A

B

C

5

4

3

2

1

Curative Non-curative

Since 2016 new cancer medicines or indications approved by the European Medicines Agency have been scored and presented either in the ESMO Guidelines where relevant or as an e-Update

Medicines which obtain the highest scores A and B (curative setting) 5 and 4 (non-curative setting) represent the highest priority for rapid endorsement by national bodies across Europe

ENSURING ACCESS TO CANCER MEDICINESA critical issue for medical oncologists

To treat patients according to the ESMO

Clinical Practice Guidelines, medical

oncologists need to have access to the cancer

medicines recommended in the guidelines.

In Europe ESMO works closely with the European

Medicines Agency and the European Network of

Health Technology Assessment in order to harmonise the approval

and reimbursement process for cancer

medicines in Europe.

ESMO has conducted international surveys on the availability of cancer

medicines and has proposed

recommendations on how to reduce the

barriers.

ESMO keeps its members updated on the latest in personalised medicine, immunotherapies and biosimilars in a rapidly-advancing landscape of new cancer treatments

ESMO: MEDICAL ONCOLOGY EDUCATION BROUGHT DIRECTLY TO YOU

A global society with a tailored education offer to meet your local needs

14-16 FEBRUARY 2018

ESMO SUMMIT AFRICA 2018 Cape Town, South Africa, 14 - 16 Feb

Oncology Updates: From Evidence to Practice

Designed to address the specific challenges faced by oncology professionals practising in this region

Local and international experts covering the cancer types most frequently encountered in Sub-Saharan Africa

Series of clinical case presentations followed by time for discussion

To provide the oncology community with a summary of the most significant treatment advances presented at the ESMO annualcongress

To review the current standard of care for key malignancies from a local and international perspective

To discuss the current controversies in the management of specific cancers

PARTICIPANTS OVERVIEW

ESMO SUMMIT AFRICA 2018

Participants Category

Speakers and chairs 44

Delegates 329

ESMO Staff 2

Total 375

COUNTRY BREAK DOWN (DELEGATES)

Country Nr. of delegatesAngola 1Austria 1Belgium 3Botswana 4Congo 5Egypt 1France 7India 1Kenya 6Mauritius 1Mozambique 1Namibia 4Netherlands 1Philippines 1Romania 1South Africa 260South Korea 1Sri Lanka 1Swaziland 3Sweden 1Switzerland 4Tanzania 4Thailand 2UK 4USA 3Zambia 2Zimbabwe 6

329

79% South Africa

11,5% Africa

6,7% Europe

1,9% Asia

0,9% Other

THANK YOU